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Long-term Aims (>6yrs): 
Recombinant vaccine 
 
Short-term Aims: 
Identify genes involved in 
virulence 
 
Why genome transplantation? 
Offers a rapid and site directed 
way of altering the genome:  
 
Once the genome is in yeast we 
can easily target any gene of 
interest, using the yeast genetic 
manipulation toolbox. 
 
For example TREC (tandem 
repeat coupled with 
endonuclease cleavage): 
Offering seamless deletions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accelerating CBPP research towards 
a better vaccine through the 
application of genome transplantation 
 
Elise Schieck & Joerg Jores 
•  Friedrich-Löffler- Institute, Germany 
•  J Craig Venter™ Institute, USA 
•  INRA, France 
 
We are collaborating with This project is currently funded by 
Tom Olaka from  
Karamoja Uganda 
 
Where are we now? 
 
All steps in the genome 
transplantation cycle have been 
performed by us using 
Mycoplasma mycoides subsp. 
capri 
 
The insertion of a yeast vector 
into the genome of Mycoplasma 
mycoides subsp. mycoides is  
ongoing. 
 
First knock-outs of putative 
virulence genes (n=2) have been 
done, now awaiting back-
transplantation to Mycoplasma 
cells followed by in vitro testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Contagious bovine pleuropneumonia (CBPP) caused by Mycoplasma mycoides subsp. mycoides (Mmm) is one of the most important livestock diseases in 
sub-Saharan Africa. CBPP impacts health and poverty of livestock-dependent people through decreased animal productivity, reduced food supply, and the 
cost of control measures. Additionally, CBPP is a barrier to trade in many African countries and this reduces the value of livestock and the income of many 
value chain stakeholders. 
 
Presently control of CBPP relies mainly on a live vaccine of limited efficacy and duration of immunity. Vaccines with better efficacy are necessary for 
control and eradication programmes within all African regions. 
 
The identification of Mycoplasma target molecules for vaccines has been hampered by the non-existence of genetic tools to manipulate the pathogen’s 
genome in a systematic way.  Recently, techniques for the targeted mutagenesis of the closely related Mycoplasma species Mycoplasma mycoides subsp. 
capri (Mmc) have been developed as part of synthetic biology efforts. Yeast is used as a host cell for the whole Mycoplasma genome, opening up to the 
fast and efficient genome manipulation toolbox for yeast. Back-transplantation of the genome to Mycoplasma cells will enable the subsequent testing of 
targeted genes for their role in host pathogen interactions using in vitro and in vivo systems. 
 
Targeted mutagenesis will accelerate the knowledge gain with respect to pathogenicity and host specificity and therefore vaccine development.  
We are in the process of transferring the genome transplantation technology to ILRI in Africa and adapting the method to field strains of Mycoplasma 
mycoides subsp. mycoides. We have also started the procedure of targeted mutagenesis of putative virulence genes in the already established 
Mycoplasma mycoides subsp. capri model  
